🇨🇦 Hu3F8 in Canada

Hu3F8 (NAXITAMAB) regulatory status in Canada.

Marketing authorisation

Hu3F8 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in Canada

Frequently asked questions

Is Hu3F8 approved in Canada?

Yes. Health Canada has authorised it.

Who is the marketing authorisation holder for Hu3F8 in Canada?

Y-Mabs Therapeutics Inc is the originator. The local marketing authorisation holder may differ — check the official source linked above.